- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01072955
Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass
January 27, 2011 updated by: Azidus Brasil
The primary objective of this study is to verify, through a randomized, blinded, parallel clinical trial, the efficacy of bovine heparin from Eurofarma Laboratory product when compared to porcine heparin APP Pharmaceutical in patients undergoing surgery cardiovascular disease and who require cardiopulmonary bypass, through the control of hemostasis during and after surgery, based on measurements of markers of coagulation ACT, aPTT, anti-Xa heparin levels and the excessive blood loss (hemorrhage) after the end of surgery.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
104
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
São Paulo
-
Valinhos, São Paulo, Brazil, 13276-245
- Recruiting
- LAL Clínica Pesquisa e Desenvolvimento Ltda
-
Contact:
- Karina Guerra
- Phone Number: +551938293822
- Email: karina@lalclinica.com.br
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who agree with all aspects of the study and sign the FICT;
- Patients of both sexes;
- Patients over the age of 18 years;
- Patients with indication for cardiac surgery requiring cardiopulmonary bypass.
Exclusion Criteria:
- Patients with hematological disorders that compromise the surgical outcome (eg, myeloproliferative disorders, anemia, Hb <11.0 g / dL, platelets <100,000 mm3);
- Patients with disorders of hemostasis (INR> 1.40) (APTTr> 1.40);
- Patients with renal impairment (creatinine> 1.50);
- Patients with deep hyperthermia;
- Liver disease (AST and ALT> 2 times that of the reference value);
- Patients with a history of allergy to heparin or protamine;
- Patients with a history of heparin-induced thrombocytopenia;
- infection (eg endocarditis, septicemia and pneumonia);
- Reoperations;
- Use of antiplatelet agents (clopidogrel and ticlopidine) for less than 7 days;
- Use of aspirin for less than 5 days;
- Use of heparin, low molecular weight less than 24 hours;
- Use of unfractionated heparin for less than 12 hours.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: heparin of bovine origin
5.000UI/mL bottle with 5mL
|
5.000UI/mL bottle with 5mL
|
Active Comparator: heparin of porcine origin
5000 USP Heparin Units / mL vial with 10 mL vial
|
5000 USP Heparin Units / mL vial with 10 mL vial
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Coagulometric parameters markers heparin activity: ACT, APTT and Anti - Xa
Time Frame: (T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative
|
(T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Value of the total dose of heparin used, the activity and adequate reversal with the use of protamine.
Time Frame: (T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative
|
(T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Anticipated)
August 1, 2010
Study Completion (Anticipated)
October 1, 2011
Study Registration Dates
First Submitted
February 19, 2010
First Submitted That Met QC Criteria
February 19, 2010
First Posted (Estimate)
February 22, 2010
Study Record Updates
Last Update Posted (Estimate)
January 28, 2011
Last Update Submitted That Met QC Criteria
January 27, 2011
Last Verified
January 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HEPSBCCV1109BOV_EUR
- Version 2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Venous Thromboembolism
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
-
Beijing Suncadia Pharmaceuticals Co., LtdRecruitingSHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee ArthroplastyPrevention of Venous Thromboembolism After Knee ArthroplastyChina
-
Daiichi Sankyo Co., Ltd.CompletedVenous Thromboembolism | PreventionJapan
-
BayerCompletedVenous Thromboembolism | PreventionDenmark, Italy, China, Indonesia, Colombia, Portugal, United States, Australia, Korea, Republic of, Taiwan, Canada, Estonia, New Zealand, Brazil, Mexico, South Africa, Peru, United Kingdom, Latvia, India, Lithuania, Sweden, Norway
-
BayerJanssen Research & Development, LLCNot yet recruitingChildren | Congenital Heart Disease | Prevention of Venous Thromboembolism | Fontan ProcedureJapan
-
Boehringer IngelheimCompletedArthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)Austria, Canada, Czechia, Finland, Netherlands, Sweden
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
BayerCompletedTreatment of Venous Thromboembolism in Cancer Patients | Prophylaxis of Recurrent Venous Thromboembolism in Cancer PatientsUnited States
Clinical Trials on Porcine heparin
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Northwell HealthTerminatedWound Healing and Scar Quality Following Mohs Surgery and Excisional Dermatologic SurgeryUnited States
-
First Wave Bio, Inc.CompletedCystic Fibrosis (CF) | Exocrine Pancreatic Insufficiency (EPI)United States, Poland
-
First Wave Bio, Inc.CompletedCystic Fibrosis (CF) | Exocrine Pancreatic Insufficiency (EPI)United States, Poland
-
The Royal Wolverhampton Hospitals NHS TrustWithdrawn
-
University of Roma La SapienzaCompletedPartially Edentulous Maxilla, Partially Edentulous MandibleItaly
-
Genzyme, a Sanofi CompanyDiacrin/Genzyme Corporation LLCCompleted
-
Medline IndustriesWithdrawn
-
Hamilton Health Sciences CorporationCanadian Institutes of Health Research (CIHR); DePuy Orthopaedics; London Health...Unknown